The technology meets an increasing demand for maximum food and human safety from consumers worldwide.
"The bacteriophage technology we acquired aims at reducing the presence of E. coli, Salmonella and Campylobacter contamination by 85-95%. We see this as a gigantic step towards major improvements of the global food safety," says Jan Kuhlmann, VP Animal Health & Nutrition, Chr. Hansen.
Products treating Salmonella and Campylobacter are in the development stage and will be launched globally upon development and regulatory approval.
Initially, Chr. Hansen plans to launch a product against E. coli in North America. Following success, the product would be released in Australia, China and Europe.